Macquarie Group’s Zevra Therapeutics ZVRA Stock Holding History

Macquarie Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-38	Closed	-$2K	–	2382
2017 Q4	$2K	Buy	+38	New	+$2.29K	﹤0.01%	2359

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

ING Group Amsterdam, Netherlands $20.5B AUM 49.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Macquarie Group's ZVRA Position: Q1 2018 in Review

Macquarie Group sold out of Zevra Therapeutics (ZVRA) in Q1 2018, closing a stake of 38 shares — an estimated $2K sold.

Macquarie Group first reported a position in ZVRA in Q4 2017 and held it in 1 quarter. The position peaked at $2K in Q4 2017. 34 funds tracked by Wall St. Rank hold ZVRA as of Q1 2018.

Macquarie Group reported no remaining Zevra Therapeutics position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 38 Zevra Therapeutics shares in Q1 2018, an estimated $2K.
Macquarie Group first reported a position in Zevra Therapeutics in Q4 2017 and held it in 1 quarter.
Macquarie Group's Zevra Therapeutics position peaked at $2K in Q4 2017.
34 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.